Sorrento Therapeutics Inc

NASDAQ:SRNE   3:59:59 PM EDT
8.27
-0.05 (-0.60%)
Regulatory, Other Pre-Announcement

Scilex Holding Company Announces Complete Enrollment Of Its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program

Published: 07/20/2021 18:08 GMT
Sorrento Therapeutics Inc (SRNE) - :scilex Holding Company - Announces Complete Enrollment of Its Sp-102 (semdexa) Phase 3 Pivotal Trial Clear.
Program.
Scilex Holding Company - Top-line Data From Phase 3 Pivotal Trial Clear.
Program is Expected in Q4 2021.
Scilex Holding Company - If Results From Clear.
Trial Are Positive, We Plan to Request Meeting With U.S. FDA by H1 2022 to Negotiate NDA Filing.